Guardant Health Inc
F:5GH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Guardant Health Inc
F:5GH
|
US |
|
G
|
Gorman-Rupp Co
NYSE:GRC
|
US |
|
C
|
Carnival Corp
LSE:0EV1
|
US |
|
Capital One Financial Corp
NYSE:COF
|
US |
|
Burckhardt Compression Holding AG
F:B5H
|
CH |
|
H
|
HSBC Holdings PLC
F:HBC1
|
UK |
|
F
|
Fujitsu Ltd
XBER:FUJ1
|
JP |
|
China Minsheng Banking Corp Ltd
OTC:CGMBF
|
CN |
|
P
|
Prysmian SpA
SWB:AEU
|
IT |
|
Shenzhou International Group Holdings Ltd
F:S6LA
|
CN |
|
T
|
Talanx AG
DUS:TLX
|
DE |
|
Molson Coors Beverage Co
F:NY70
|
US |
|
PennyMac Financial Services Inc
NYSE:PFSI
|
US |
Guardant Health Inc
Guardant Health makes blood-based tests for cancer. Its main products are liquid biopsy tests that look for tumor DNA in a patient’s blood, helping doctors detect cancer, choose treatment, and watch for signs that disease may be returning. The company sells these tests to oncologists, hospitals, health systems, and patients through the medical care process. The business makes money in two main ways: it is paid for running diagnostic tests for patients, and it also sells testing and data services to drugmakers that are developing cancer therapies. That second line of business helps biopharma companies find the right patients for clinical trials and study how cancers respond to treatment. Guardant sits at the intersection of lab testing and cancer care. Instead of requiring a tissue biopsy in every case, it offers a simpler blood draw that can give doctors genetic information about a tumor. That makes the company a specialist supplier in precision oncology, where test results can directly influence treatment decisions.
Guardant Health makes blood-based tests for cancer. Its main products are liquid biopsy tests that look for tumor DNA in a patient’s blood, helping doctors detect cancer, choose treatment, and watch for signs that disease may be returning. The company sells these tests to oncologists, hospitals, health systems, and patients through the medical care process.
The business makes money in two main ways: it is paid for running diagnostic tests for patients, and it also sells testing and data services to drugmakers that are developing cancer therapies. That second line of business helps biopharma companies find the right patients for clinical trials and study how cancers respond to treatment.
Guardant sits at the intersection of lab testing and cancer care. Instead of requiring a tissue biopsy in every case, it offers a simpler blood draw that can give doctors genetic information about a tumor. That makes the company a specialist supplier in precision oncology, where test results can directly influence treatment decisions.
Beat and raise: Guardant reported Q1 revenue of $302 million, up 48% year over year, and lifted full-year 2026 revenue guidance to $1.30 billion to $1.32 billion.
Screening momentum: Shield revenue jumped to $42 million on about 44,000 tests, with management saying March accelerated sharply thanks to DTC, HCP marketing, Quest, and stronger rep productivity.
Oncology strength: Oncology revenue rose 36% to $205 million, helped by 47% test volume growth and broad adoption across Liquid, Tissue, and Reveal.
Reveal traction: Reveal remained the fastest-growing oncology product, with volume up over 100% year over year and stronger therapy monitoring adoption adding momentum.
Margin progress: Gross margin improved to 66%, while Screening gross margin rose sharply to 56% as Shield pricing and lower per-test costs improved economics.
Cash and spending: Operating expenses rose as Guardant kept investing in commercial growth, but management said full-year free cash flow burn should improve versus 2025 and that company-wide cash flow breakeven is still targeted by end-2027.
